Prophylactic use of liposomal amphotericin B in children and adolescents undergoing allogeneic hematopoietic cell transplantation: A 10-years single center experience
Laura G.Y. Rotte(Princess Máxima Center), Tom F.W. Wolfs(KU Leuven), Caroline A. Lindemans(University Medical Center Utrecht), Marc Bierings(University Medical Center Utrecht), Coco de Koning(University Medical Center Utrecht), Yvette G.T. Loeffen(Wilhelmina Children's Hospital), Jaap Jan Boelens(Wilhelmina Children's Hospital)
Cited by 1
Related Papers
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial
|The Lancet|2012|376
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study
|Journal of Clinical Oncology|2020|333